This halfway evaluation of SBBC indicates steady trends toward a 50% reduction in 24-hour newborn mortality, and a 10–20% reduction in maternal mortality in four of five regions. Reported FSB rates seem to be stable in two regions and worse in three regions. We described differences between the regions and potential relations between key performance clinical indicators and perinatal mortality, and hence, areas for improvements as we move forward. Despite increased survival rates that are in line with our hypotheses, these preliminary data indicate that there is a remaining impact potential if uptake of the bundle is further strengthened over time.